Scientists test Immune-Boosting shot for motor neuron disease
NCT ID NCT02059759
Summary
This study tested whether adding a low-dose immune therapy called interleukin-2 to standard ALS medication (riluzole) is safe and affects immune cells. It involved 36 adults with ALS who received either the therapy or a placebo in addition to their regular medication. The main goal was to see how the treatment changed specific immune cells and to check for side effects over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.